Browsing Tag
oncology imaging
3 posts
Is Lantheus (LNTH) the next big radiopharma target after Curium’s takeover move?
Curium’s $7B Lantheus move exposes radiopharma’s scarcity premium. See why oncology imaging assets are becoming M&A targets.
A small imaging trial could reshape how brain metastases are detected and Radiopharm Theranostics is betting on it (ASX: RAD)
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Discover the strategic and market implications.
Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis
Radiopharm Theranostics RAD 101 achieves 90% PET-MRI concordance in brain metastases Phase 2b trial. Full data due June 2026. Read more.